Eversept Partners, LP Apellis Pharmaceuticals, Inc. Transaction History

Eversept Partners, LP

$1.26 Billion
Q3 2024

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $1.57 Million - $5.91 Million	66,194 Added 117.26%	122,643 $4.67 Million
Q2 2023 Nov 08, 2023	SELL	$76.68 - $93.31 $7.54 Million - $9.18 Million	-98,347 Reduced 63.53%	56,449 $5.14 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $4.33 Million - $5.27 Million	56,449 New	56,449 $5.14 Million
Q4 2022 Nov 08, 2023	BUY	$43.24 - $61.04 $4.25 Million - $6 Million	98,347 Added 174.22%	154,796 $8 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $6.69 Million - $9.45 Million	154,796 New	154,796 $8 Million
Q2 2021 Aug 16, 2021	SELL	$40.9 - $64.9 $527,610 - $837,210	-12,900 Closed	0 $0
Q1 2021 Nov 08, 2023	BUY	$40.8 - $57.39 $370,627 - $521,330	9,084 Added 238.05%	12,900 $553,000
Q1 2021 May 13, 2021	BUY	$40.8 - $57.39 $370,627 - $521,330	9,084 Added 238.05%	12,900 $554,000
Q4 2020 Nov 08, 2023	SELL	$30.79 - $57.2 $1.62 Million - $3.01 Million	-52,633 Reduced 93.24%	3,816 $218,000
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $2.38 Million - $4.43 Million	-77,451 Reduced 95.3%	3,816 $218,000
Q3 2020 Nov 08, 2023	SELL	$25.89 - $33.65 $8.79 Million - $11.4 Million	-339,665 Reduced 80.69%	81,267 $2.45 Million
Q3 2020 Nov 13, 2020	SELL	$25.89 - $33.65 $8.79 Million - $11.4 Million	-339,665 Reduced 80.69%	81,267 $2.45 Million
Q2 2020 Nov 08, 2023	SELL	$24.8 - $38.49 $11.9 Million - $18.4 Million	-478,542 Reduced 53.2%	420,932 $13.7 Million
Q2 2020 Aug 13, 2020	SELL	$24.8 - $38.49 $11.9 Million - $18.4 Million	-478,542 Reduced 53.2%	420,932 $13.7 Million
Q1 2020 Nov 08, 2023	BUY	$17.91 - $44.33 $10.6 Million - $26.1 Million	589,065 Added 189.77%	899,474 $24.1 Million
Q1 2020 May 13, 2020	BUY	$17.91 - $44.33 $10.6 Million - $26.1 Million	589,065 Added 189.77%	899,474 $24.1 Million
Q4 2019 Nov 08, 2023	BUY	$22.1 - $30.8 $5.1 Million - $7.11 Million	230,900 Added 290.41%	310,409 $9.5 Million
Q4 2019 Feb 13, 2020	BUY	$22.1 - $30.8 $5.1 Million - $7.11 Million	230,900 Added 290.41%	310,409 $9.51 Million
Q3 2019 Nov 08, 2023	SELL	$24.09 - $32.18 $910,602 - $1.22 Million	-37,800 Reduced 32.22%	79,509 $1.92 Million
Q3 2019 Nov 13, 2019	SELL	$24.09 - $32.18 $910,602 - $1.22 Million	-37,800 Reduced 32.22%	79,509 $1.92 Million
Q2 2019 Nov 08, 2023	BUY	$18.0 - $25.34 $233,280 - $328,406	12,960 Added 12.42%	117,309 $2.97 Million
Q2 2019 Aug 13, 2019	BUY	$18.0 - $25.34 $233,280 - $328,406	12,960 Added 12.42%	117,309 $2.97 Million
Q1 2019 Nov 08, 2023	SELL	$12.81 - $19.82 $32,422 - $50,164	-2,531 Reduced 2.37%	104,349 $2.03 Million
Q1 2019 May 14, 2019	SELL	$12.81 - $19.82 $32,422 - $50,164	-2,531 Reduced 2.37%	104,349 $2.04 Million
Q4 2018 Nov 08, 2023	BUY	$11.47 - $18.71 $75,529 - $123,205	6,585 Added 6.57%	106,880 $1.41 Million
Q4 2018 Feb 13, 2019	BUY	$11.47 - $18.71 $75,529 - $123,205	6,585 Added 6.57%	106,880 $1.41 Million
Q3 2018 Nov 08, 2023	BUY	$16.57 - $21.03 $31,483 - $39,957	1,900 Added 1.93%	100,295 $1.78 Million
Q3 2018 Nov 14, 2018	BUY	$16.57 - $21.03 $31,483 - $39,957	1,900 Added 1.93%	100,295 $1.78 Million
Q2 2018 Nov 08, 2023	BUY	$19.63 - $30.0 $823,399 - $1.26 Million	41,946 Added 74.31%	98,395 $2.16 Million
Q2 2018 Aug 14, 2018	BUY	$19.63 - $30.0 $1.93 Million - $2.95 Million	98,395 New	98,395 $2.17 Million

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

Wellington Management Group LLP Boston, MA

15.6M
Shares

$516 Million
0.08% of portfolio
Eco R1 Capital, LLC San Francisco, CA

11.9M
Shares

$394 Million
14.88% of portfolio
Avoro Capital Advisors LLC New York, NY

11.1M
Shares

$368 Million
4.82% of portfolio
Vanguard Group Inc Valley Forge, PA

9.82M
Shares

$325 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.8M
Shares

$192 Million
0.01% of portfolio

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Account